- Home »
- Market Insights »
- Upcoming Biotech Phase 3 Trial Readouts (June 2026)
Upcoming Biotech Phase 3 Trial Readouts (June 2026)
A calendar of upcoming biotech Phase 3 trial readouts tracked by MarketsHost from public regulatory and clinical-trial sources. Informational only.
by Mubarak
Published Jun 14, 2026 | Updated Jul 22, 2026 | 📖 3 min read
Article continues below advertisement
This calendar tracks upcoming Phase 3 clinical trial readouts for biotechnology companies, organized by expected announcement date. Each entry pairs a company and ticker symbol with a specific drug candidate or development program. Dates are sourced from public regulatory filings and clinical trial registries, though timelines may shift as development progresses.
Phase 3 trial outcomes represent critical inflection points for biotech firms and investors alike. These readouts influence market perception, inform regulatory pathways, and chart the course of clinical development. For those following the sector, monitoring these milestones offers crucial visibility into the pipeline progress of major biotech players and signals within the broader innovation space.
Upcoming Biotech Phase 3 Readouts
| # | Date | Company | Ticker | Drug / Trial |
|---|---|---|---|---|
| 1 | Jul 23, 2026 | BioNTech SE | BNTX | A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in H… |
| 2 | Jul 24, 2026 | JOHNSON & JOHNSON | JNJ | A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in … |
| 3 | Jul 24, 2026 | Bio Green Med Solution, Inc. | BGMS | Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension |
| 4 | Jul 30, 2026 | Quoin Pharmaceuticals, Ltd. | QNRX | Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome |
| 5 | Jul 31, 2026 | BeOne Medicines Ltd. | ONC | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tisleli… |
| 6 | Jul 31, 2026 | BioNTech SE | BNTX | A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Yea… |
| 7 | Jul 31, 2026 | HST Global, Inc. | HSTC | A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 i… |
| 8 | Aug 1, 2026 | Arcus Biosciences, Inc. | RCUS | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelima… |
| 9 | Aug 1, 2026 | Mirum Pharmaceuticals, Inc. | MIRM | A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chron… |
| 10 | Aug 1, 2026 | Grifols SA | GRFS | Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process … |
| 11 | Aug 1, 2026 | Xenon Pharmaceuticals Inc. | XENE | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder |
| 12 | Aug 1, 2026 | Ovid Therapeutics Inc. | OVID | A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) |
| 13 | Aug 1, 2026 | Kodiak Sciences Inc. | KOD | A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabira… |
| 14 | Aug 1, 2026 | Pharvaris N.V. | PHVS | Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against A… |
| 15 | Aug 1, 2026 | Alto Neuroscience, Inc. | ANRO | To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With M… |
| 16 | Aug 1, 2026 | Invivyd, Inc. | IVVD | Study of VYD2311 for the Prevention of COVID-19 |
| 17 | Aug 1, 2026 | Sol-Gel Technologies Ltd. | SLGL | Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas … |
| 18 | Aug 1, 2026 | Karyopharm Therapeutics Inc. | KPTI | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With… |
| 19 | Aug 1, 2026 | Ensysce Biosciences, Inc. | ENSC | PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301) |
| 20 | Aug 1, 2026 | NEUTRA CORP. | NTRR | A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Particip… |
How this list is compiled
Events are sourced from public US-government and clinical-trial data (SEC filings, the Federal Register and ClinicalTrials.gov) and ordered by date. Dates can change; always confirm with primary sources. Figures are pulled automatically from MarketsHost data and refreshed regularly. This page is for general information only and is not investment, financial or trading advice.
For the underlying data, explore the BioPharma FDA catalyst tracker on MarketsHost.
Related Articles
Frequently Asked Questions
. What is a Phase 3 readout?
A Phase 3 readout is the release of results from a large, late-stage clinical trial — a key milestone in a drug's path to potential approval.
. Are these dates guaranteed?
No. Regulatory and trial timelines can move. The calendar reflects the most recent public estimates and should be confirmed against primary sources.
Disclaimer : The above information is for general informational purposes only. All information on the Site is provided in good faith, however we make no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, availability or completeness of any information on the Site.